Answers are grounded in this paper and cite their sources.
Over the past decade, significant advancements in the field of melanoma have included the introduction of a new staging system and the development of immunotherapy and targeted therapies, leading to changes in substage classification and impacting patient prognosis. Despite these strides, early detection remains paramount. The quest for dependable prognostic biomarkers is ongoing, given melanoma's unpredictable nature, especially in identifying patients at risk of relapse. Reliable biomarkers are critical for informed treatment decisions.
No takes yet. Share an insight, caveat, or question.
Roccuzzo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: